In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 8_Supplement ( 2011-04-15), p. LB-182-LB-182
Abstract:
The serum level of homocysteine is suggested to be related to inflammation, cardiovascular disease, and cancer. This study aimed to evaluate preoperative serum homocysteine level as biomarker for breast cancer prognosis. We measured serum homocysteine levels using the fluorescence polarization in 370 participants who were newly diagnosed and histopathologically confirmed breast cancer from hospitals located in Seoul, Korea between 2004 and 2007. Univariate and multivariate analyses were used to investigate association between serum homocysteine level and disease free survival. The median concentration of homocysteine was 10.09 ng/mL and interquartile range was 8.4–12.6. Kaplan-Meier curves showed that the elevated concentration of homocysteine was associated with poor disease-free survival (log rank p = 0.02). In multivariate analysis using the Cox's proportional hazard regression model, patients with greater than median levels of homocysteine showed increased risk of breast cancer recurrence compared to the patients with lower levels of homocysteine after adjusting for factors related to prognosis (hazard ratio = 2.03; 95% confidence interval, 1.13–3.64; p = 0.02). These findings suggest that higher level of homocysteine may be associated with the poor prognosis of breast cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-182. doi:10.1158/1538-7445.AM2011-LB-182
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/1538-7445.AM2011-LB-182
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2011
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
